Suzhou Eyre cleared for penicillin production by SFDA
Suzhou Erye Pharmaceutical has received SFDA approval to make penicillin at its new manufacturing facility in Eastern China.
The firm, a subsidiary of US stem cell specialist NeoStem, has got the OK to make both solvent crystallised and freeze dried raw sterile penicillin at the plant, which generates 20 per cent of its income each year.
NeoStem CEO Robin Smith said that gaining Chinese Food and Drug Administration (SFDA) approval is part of a wider project to transfer manufacturing operations to the new facility over the next 12 months.
“Once Erye has completed its relocation to the new facility, and its new production lines are fully operational, it will have substantially increased its capacity from the current plant with the goal of becoming among the largest antibiotic producers in Eastern China."
